Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Sorrento Shares Pop After Interim Data From Lung Cancer Trial

Published 23/08/2022, 16:58
Updated 23/08/2022, 17:41
© Reuters.  Sorrento Shares Pop After Interim Data From Lung Cancer Trial

  • Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.
  • Abivertinib selectively inhibits EGFR-activating and resistant mutation with nearly 300-fold greater potency than wild-type EGFR.
  • In these Independent Review Committee (IRC)-assessed preliminary data, Abivertinib showed significant treatment benefits in 209 response evaluable, heavily treated NSCLC patients with an ORR of 56.5%.
  • Related: Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer.
  • A significant CR rate was seen with Abivertinib (5.3%) compared to AstraZeneca Plc's (NASDAQ: NASDAQ:AZN) Tagrisso (osimertinib) (0.5%), while the ORR rate is comparable between the two drugs.
  • Overall survival was 28.2 months (versus Tagrisso's median OS of 26.8 months).
  • Sorrento is preparing the pre-FDA marketing application materials and package.
  • Price Action: SRNE shares are up 5.51% at $1.87 on the last check Tuesday.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.